Good morning from Day 2 from #AIDS2022, first talk, the possibility of HIV mRNA Vaccine
Difficulties - HIV integrates into DNA, highly mutable, and complex response to HIV envelope glycoprotein
Difficulties - HIV integrates into DNA, highly mutable, and complex response to HIV envelope glycoprotein
An mRNA vaccine was able to create broadly neutralizing antibodies however much different landscape on surface of HIV compared to SARS-COV-2
mRNA sticks around, is cheap to produce, easily modified, and creates endogenous protein
Of course vaccine equity is v important #AIDS2022
mRNA sticks around, is cheap to produce, easily modified, and creates endogenous protein
Of course vaccine equity is v important #AIDS2022
Possibility to Prime, then boost multiple times to create broadly neutralizing Abs, would require multiple clinical trials
IAVI G001 - 2 immunizations of vaccine, low dose and high dose arms, well tolerated, 94-97% response, increased mutation levels on second vaccine #AIDS2022
IAVI G001 - 2 immunizations of vaccine, low dose and high dose arms, well tolerated, 94-97% response, increased mutation levels on second vaccine #AIDS2022
G002 (US), G003 (Africa), HVTN 302 Phase 1 trials in collaboration with Moderna, in the hopes to speed and advance trials
HVTN302 looking at delivery of HIV soluble and membrane bound trimers, as well as to try and see if affecting CD4 affinity has effect
#AIDS2022
HVTN302 looking at delivery of HIV soluble and membrane bound trimers, as well as to try and see if affecting CD4 affinity has effect
#AIDS2022
• • •
Missing some Tweet in this thread? You can try to
force a refresh
